Drug Profile

TL 05

Alternative Names: TL-05

Latest Information Update: 28 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tilos Therapeutics
Class Anti-inflammatories; Antibodies; Antifibrotics
Mechanism of Action Immunomodulators; Transforming growth factor beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2022 No recent reports of development identified for research development in Fibrosis in USA (Parenteral)
30 Jul 2019 Tilos Therapeutics has been acquired by Merck & Co
14 Aug 2018 Tilos Therapeutics plans early proof-of-concept preclinical trials for Fibrosis in USA (Tilos Therapeutics website, August 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com